Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science
Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the significant advantages of its proprietary JOTROL™ platform over traditional resveratrol formulations. The company's breakthrough demonstrates 9x higher bioavailability compared to conventional resveratrol, without gastrointestinal side effects at therapeutic doses.
JOTROL™ has shown ability to cross the blood-brain barrier and is advancing to Phase IIa trials for Parkinson's Disease. The platform's intellectual property is secured through 2036 across major markets. Jupiter plans to launch its Nugevia™ consumer product line in Q3 2025, featuring formulations for cognitive health, mitochondrial energy, and skin vitality.
Jupiter Neurosciences (NASDAQ: JUNS) ha evidenziato i vantaggi significativi della sua piattaforma proprietaria JOTROL™ rispetto alle formulazioni tradizionali di resveratrolo. L'innovazione dell'azienda dimostra una biodisponibilità 9 volte superiore rispetto al resveratrolo convenzionale, senza effetti collaterali gastrointestinali a dosi terapeutiche.
JOTROL™ ha mostrato la capacità di attraversare la barriera emato-encefalica ed è in avanzamento verso trial di Fase IIa per il Morbo di Parkinson. La proprietà intellettuale della piattaforma è protetta fino al 2036 nei principali mercati. Jupiter prevede di lanciare la sua linea di prodotti consumer Nugevia™ nel terzo trimestre 2025, con formulazioni dedicate alla salute cognitiva, all'energia mitocondriale e alla vitalità della pelle.
Jupiter Neurosciences (NASDAQ: JUNS) ha destacado las ventajas significativas de su plataforma patentada JOTROL™ sobre las formulaciones tradicionales de resveratrol. El avance de la compañía demuestra una biodisponibilidad 9 veces mayor en comparación con el resveratrol convencional, sin efectos secundarios gastrointestinales a dosis terapéuticas.
JOTROL™ ha mostrado capacidad para cruzar la barrera hematoencefálica y está avanzando hacia ensayos de Fase IIa para la Enfermedad de Parkinson. La propiedad intelectual de la plataforma está asegurada hasta 2036 en los principales mercados. Jupiter planea lanzar su línea de productos para consumidores Nugevia™ en el tercer trimestre de 2025, con formulaciones para la salud cognitiva, la energía mitocondrial y la vitalidad de la piel.
Jupiter Neurosciences (NASDAQ: JUNS)는 기존 레스베라트롤 제형에 비해 자사의 독점 플랫폼 JOTROL™의 뛰어난 장점을 강조했습니다. 이 회사의 혁신은 기존 레스베라트롤 대비 9배 높은 생체이용률을 치료 용량에서 위장 부작용 없이 입증했습니다.
JOTROL™은 혈뇌장벽을 통과하는 능력을 보였으며 파킨슨병 대상 2a상 임상시험으로 진행 중입니다. 이 플랫폼의 지적 재산권은 주요 시장에서 2036년까지 보호됩니다. Jupiter는 인지 건강, 미토콘드리아 에너지, 피부 활력을 위한 제형을 포함한 소비자용 제품 라인 Nugevia™를 2025년 3분기에 출시할 계획입니다.
Jupiter Neurosciences (NASDAQ : JUNS) a mis en avant les avantages significatifs de sa plateforme propriétaire JOTROL™ par rapport aux formulations traditionnelles de resvératrol. L'innovation de la société démontre une biodisponibilité 9 fois supérieure à celle du resvératrol conventionnel, sans effets secondaires gastro-intestinaux aux doses thérapeutiques.
JOTROL™ a montré sa capacité à traverser la barrière hémato-encéphalique et progresse vers des essais de phase IIa pour la maladie de Parkinson. La propriété intellectuelle de la plateforme est protégée jusqu'en 2036 sur les principaux marchés. Jupiter prévoit de lancer sa ligne de produits grand public Nugevia™ au troisième trimestre 2025, avec des formulations dédiées à la santé cognitive, à l'énergie mitochondriale et à la vitalité de la peau.
Jupiter Neurosciences (NASDAQ: JUNS) hat die bedeutenden Vorteile seiner proprietären JOTROL™-Plattform gegenüber herkömmlichen Resveratrol-Formulierungen hervorgehoben. Der Durchbruch des Unternehmens zeigt eine 9-fach höhere Bioverfügbarkeit im Vergleich zu konventionellem Resveratrol, ohne gastrointestinale Nebenwirkungen bei therapeutischen Dosen.
JOTROL™ hat die Fähigkeit gezeigt, die Blut-Hirn-Schranke zu überwinden, und befindet sich in der Weiterentwicklung zu Phase-IIa-Studien für die Parkinson-Krankheit. Das geistige Eigentum der Plattform ist bis 2036 in den wichtigsten Märkten gesichert. Jupiter plant die Einführung seiner Nugevia™-Verbraucherproduktlinie im dritten Quartal 2025, mit Formulierungen für kognitive Gesundheit, mitochondriale Energie und Hautvitalität.
- None.
- Early clinical stage - still in Phase I/IIa development
- Efficacy in human trials for Parkinson's Disease not yet proven
Insights
JOTROL™ solves resveratrol's bioavailability problem, advancing to Phase IIa for Parkinson's with strong commercial potential.
Jupiter Neurosciences has engineered a significant pharmaceutical advancement with JOTROL™, addressing the fundamental limitations that have previously prevented resveratrol from becoming a viable therapeutic. The 9-fold increase in bioavailability demonstrated in Phase I trials represents a genuine breakthrough in drug delivery science, particularly for CNS applications. The ability to achieve therapeutic plasma concentrations without the dose-limiting GI toxicity seen with conventional formulations (>5g required for efficacy) is the critical distinction that gives this platform legitimate clinical potential.
Most important is JOTROL's demonstrated ability to cross the blood-brain barrier, which opens therapeutic pathways for neurological conditions where treatment options remain severely limited. The preclinical efficacy in the MPTP Parkinson's model showing motor improvements provides tangible evidence supporting their upcoming Phase IIa trial strategy. Their intellectual property position with protection through 2036 across major markets creates a substantial competitive moat.
The dual-track commercialization approach is particularly shrewd - developing high-value pharmaceutical applications while generating near-term revenue through consumer products. This strategy provides both cash flow potential and multiple shots on goal for shareholders. The mechanistic focus on mitochondrial biogenesis through AMPK/SIRT1 activation aligns with current scientific understanding of neurodegenerative pathways, giving their approach strong biological plausibility. While still early-stage, JOTROL™ represents a meaningful technological advancement with clear development pathways toward multiple CNS indications.
Transforming a promising molecule into a clinically viable therapeutic platform
Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL™, over conventional resveratrol formulations.
Unlocking Resveratrol’s Therapeutic Promise
Resveratrol is one of the world’s most researched molecules and has long been studied for its powerful antioxidant, mitochondrial, and anti-inflammatory effects. However, achieving therapeutic benefit has proven elusive due to the molecule’s extremely poor bioavailability and dose-limiting gastrointestinal (GI) side effects.
“Clinical studies have shown that to reach the minimum effective plasma concentration of over 250 ng/mL a patient would need to ingest approximately 5 grams of today’s marketed resveratrol products,” explained Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “At those levels, severe GI issues are nearly guaranteed, effectively halting any realistic therapeutic use.”
A Pharmaceutical-Grade Breakthrough
JOTROL™ was developed specifically to overcome these critical limitations. In a Phase I clinical trial, JOTROL™ achieved a nine-fold increase in bioavailability compared to traditional resveratrol, without the GI toxicity seen at high doses. This proprietary formulation enables systemic therapeutic dosing with significantly reduced pill burden and enhanced tolerability.
Key Differentiators:
- Approximately 9 times higher bioavailability at peak plasma concentration versus naïve resveratrol
- No GI side effects observed at therapeutic levels
- Secured intellectual property in the U.S., EU, China, Japan, and Hong Kong through 2036
- Demonstrated ability to reach the central nervous system by passing the blood brain barrier, a critical factor for diseases such as Parkinson’s, Alzheimer’s, and MELAS
A Platform for Clinical Development and Commercial Growth
JOTROL™ is currently advancing toward a Phase IIa trial in Parkinson’s Disease, following breakthrough preclinical data in a well-established MPTP mouse model that demonstrated meaningful improvements in motor functions. The same delivery technology is also being used in Jupiter’s Nugevia™ consumer product line, launching in Q3 2025 with targeted formulations focused on cognitive health (MND), mitochondrial energy (PWR), and skin vitality (GLO).
“This is more than just a formulation. It’s a platform,” added Rosén. “Whether through pharmaceutical trials or premium consumer offerings, JOTROL™ opens entirely new pathways to address CNS diseases and longevity using the same foundational science.”
Scientific Rationale: Targeting Mitochondria and Inflammation
As shown in Jupiter’s preclinical and mechanistic studies, resveratrol, and by extension JOTROL™, works by promoting mitochondrial biogenesis through AMPK and SIRT1 activation. It also scavenges oxidative radicals and suppresses neuroinflammation. These mechanisms are increasingly recognized as central to the progression of neurodegenerative disease and systemic aging.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, includeing indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
About JOTROL
Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson’s Disease.
About Nugevia
In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter’s Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.
The Nugevia product line will be launched in Q3 of 2025 through the website Nugevia.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
JUNS@redchip.com
FAQ
What makes Jupiter Neurosciences' JOTROL™ different from traditional resveratrol?
What clinical trials is Jupiter Neurosciences (JUNS) conducting for JOTROL™?
When will Jupiter Neurosciences (JUNS) launch its consumer products?
How long is JOTROL™'s patent protection?
How does JOTROL™ work in treating neurological conditions?
